Home based rehabilitation to reduce falls and disability in Parkinson's disease (PD)

Not Applicable

Completed

• Conditions: Parkinson's disease; Neurological - Parkinson's disease; Physical Medicine / Rehabilitation - Physiotherapy

• Registration Number: ACTRN12608000390381
• Lead Sponsor: The University of Melbourne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-08-04
• Study Completion: 2012-02-01
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 143

Inclusion Criteria

1. Diagnosis of idiopathic Parkinson's disease (confirmed by a neurologist)
2. Living in the community
3. Classified on the Hoehn & Yahr scale as stage I-IV

Exclusion Criteria

(1) Suffer from a cardiopulmonary, musculoskeletal, endocrine or other medical condition that prevents safe participation in a home exercise program (as determined by the referring neurologist or medical practitioner)
(3) Participant or their care-giver/ family are unwilling to have therapy and assessments in their home
(4) Unable to communicate in English (interpreters are not available)
(5) Have dementia, score < 24 on the Mini Mental State Examination or are unable to provide informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Falls frequency for the 12 month period immediately following the home-based rehabilitation program. Falls will be recorded on a calendar by each participant and the accuracy of this information will be verified during a phone call from the researchers.[The falls calendar will be returned to the researchers monthly for the 12 months following the rehabilitation program.]

Secondary Outcome Measures

Name	Time	Method
Motor disability: Measured on the motor section of the Unified Parkinson's Disease Rating Scale[At baseline, 6 weeks (immediately post therapy) and 12 months post therapy.];Global disability: Measured as the total score on the Unified Parkinson's Disease Rating Scale[At baseline, 6 weeks (immediately post therapy) and 12 months post therapy.];Quality of Life: Measured by the PDQ39 (Parkinson's Disease Questionnaire) and the EuroQol-5D[At baseline, 6 weeks (immediately post therapy) and 12 months post therapy.];Economic data: Medicare and hospitalisation costs over the 12 month study period[12 months post therapy]